These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 32829050)

  • 1. Retention of neutralizing antibodies to Japanese encephalitis vaccine in age groups above fifteen years in Korea.
    Lee HJ; Choi H; Park KH; Jang Y; Hong YJ; Kim YB
    Int J Infect Dis; 2020 Nov; 100():53-58. PubMed ID: 32829050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sero-Molecular Epidemiology of Japanese Encephalitis in Zhejiang, an Eastern Province of China.
    Pan JR; Yan JY; Zhou JY; Tang XW; He HQ; Xie RH; Mao HY; Zhang YJ; Xie SY
    PLoS Negl Trop Dis; 2016 Aug; 10(8):e0004936. PubMed ID: 27560360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreases in Both the Seroprevalence of Serum Antibodies and Seroprotection against Japanese Encephalitis Virus among Vaccinated Children.
    Wang R; Xie L; Gao N; Fan D; Chen H; Wang P; Zhou H; An J
    Virol Sin; 2019 Jun; 34(3):243-252. PubMed ID: 30911897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low Protective Efficacy of the Current Japanese Encephalitis Vaccine against the Emerging Genotype 5 Japanese Encephalitis Virus.
    Cao L; Fu S; Gao X; Li M; Cui S; Li X; Cao Y; Lei W; Lu Z; He Y; Wang H; Yan J; Gao GF; Liang G
    PLoS Negl Trop Dis; 2016 May; 10(5):e0004686. PubMed ID: 27139722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized study of the immunogenicity and safety of Japanese encephalitis chimeric virus vaccine (JE-CV) in comparison with SA14-14-2 vaccine in children in the Republic of Korea.
    Kim DS; Houillon G; Jang GC; Cha SH; Choi SH; Lee J; Kim HM; Kim JH; Kang JH; Kim JH; Kim KH; Kim HS; Bang J; Naimi Z; Bosch-Castells V; Boaz M; Bouckenooghe A
    Hum Vaccin Immunother; 2014; 10(9):2656-63. PubMed ID: 25483480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low population Japanese encephalitis virus (JEV) seroprevalence in Udayapur district, Nepal, three years after a JE vaccination programme: A case for further catch up campaigns?
    Turtle L; Brindle HE; Schluter WW; Faragher B; Rayamajhi A; Bohara R; Gurung S; Shakya G; Yoksan S; Dixit S; Rajbhandari R; Paudel B; Adhikari S; Solomon T; Griffiths MJ
    PLoS Negl Trop Dis; 2019 Apr; 13(4):e0007269. PubMed ID: 30986252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity of live attenuated Japanese encephalitis SA 14-14-2 vaccine among Sri Lankan children with previous receipt of inactivated JE vaccine.
    Wijesinghe PR; Abeysinghe MRN; Yoksan S; Yao Y; Zhou B; Zhang L; Fleming JA; Marfin AA; Victor JC
    Vaccine; 2016 Nov; 34(48):5923-5928. PubMed ID: 27773472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Japanese encephalitis vaccine-facilitated dengue virus infection-enhancement antibody in adults.
    Saito Y; Moi ML; Takeshita N; Lim CK; Shiba H; Hosono K; Saijo M; Kurane I; Takasaki T
    BMC Infect Dis; 2016 Oct; 16(1):578. PubMed ID: 27756212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of protection against Japanese encephalitis virus and JE vaccine (IXIARO(®)) induced neutralizing antibody titers.
    Van Gessel Y; Klade CS; Putnak R; Formica A; Krasaesub S; Spruth M; Cena B; Tungtaeng A; Gettayacamin M; Dewasthaly S
    Vaccine; 2011 Aug; 29(35):5925-31. PubMed ID: 21723353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cellular Immune Responses to Live Attenuated Japanese Encephalitis (JE) Vaccine SA14-14-2 in Adults in a JE/Dengue Co-Endemic Area.
    Turtle L; Tatullo F; Bali T; Ravi V; Soni M; Chan S; Chib S; Venkataswamy MM; Fadnis P; Yaïch M; Fernandez S; Klenerman P; Satchidanandam V; Solomon T
    PLoS Negl Trop Dis; 2017 Jan; 11(1):e0005263. PubMed ID: 28135273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-protection elicited by primary and booster vaccinations against Japanese encephalitis: a two-year follow-up study.
    Erra EO; Askling HH; Yoksan S; Rombo L; Riutta J; Vene S; Lindquist L; Vapalahti O; Kantele A
    Vaccine; 2013 Dec; 32(1):119-23. PubMed ID: 24176496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens.
    Prompetchara E; Ketloy C; Keelapang P; Sittisombut N; Ruxrungtham K
    Asian Pac J Allergy Immunol; 2015 Sep; 33(3):182-8. PubMed ID: 26342114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Partially neutralizing potency against emerging genotype I virus among children received formalin-inactivated Japanese encephalitis virus vaccine.
    Fan YC; Chen JM; Chiu HC; Chen YY; Lin JW; Shih CC; Chen CM; Chang CC; Chang GJ; Chiou SS
    PLoS Negl Trop Dis; 2012; 6(9):e1834. PubMed ID: 23029592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistence of IgM Antibodies after Vaccination with Live Attenuated Japanese Encephalitis Vaccine.
    Hills SL; Van Keulen A; Feser J; Panella A; Letson GW; Staples JE; Marfin AA; Brault AC
    Am J Trop Med Hyg; 2020 Nov; 104(2):576-579. PubMed ID: 33236716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralizing antibody rather than cellular immune response is maintained for nearly 20 years among Japanese encephalitis SA14-14-2 vaccinees in an endemic setting.
    Wang R; Fan D; Wang L; Li Y; Zhou H; Gao N; An J
    Infect Genet Evol; 2020 Nov; 85():104476. PubMed ID: 32736041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protection of swine by potent neutralizing anti-Japanese encephalitis virus monoclonal antibodies derived from vaccination.
    Young CL; Lyons AC; Hsu WW; Vanlandingham DL; Park SL; Bilyeu AN; Ayers VB; Hettenbach SM; Zelenka AM; Cool KR; Peterson GJ; Higgs S; Huang YS
    Antiviral Res; 2020 Feb; 174():104675. PubMed ID: 31825852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modeling the long-term persistence of neutralizing antibody in children and toddlers after vaccination with live attenuated Japanese encephalitis chimeric virus vaccine.
    Bouckenooghe A; Bailleux F; Feroldi E
    Hum Vaccin Immunother; 2019; 15(1):72-79. PubMed ID: 30230947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term Immunogenicity of a Single Dose of Japanese Encephalitis Chimeric Virus Vaccine in Toddlers and Booster Response 5 Years After Primary Immunization.
    Kosalaraksa P; Watanaveeradej V; Pancharoen C; Capeding MR; Feroldi E; Bouckenooghe A
    Pediatr Infect Dis J; 2017 Apr; 36(4):e108-e113. PubMed ID: 28030526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Japanese encephalitis protein vaccine candidates expressing neutralizing epitope and M.T hsp70 induce virus-specific memory B cells and long-lasting antibodies in swine.
    Fei-fei G; Jian W; Feng X; Li-ping S; Quan-yun S; Jin-ping Z; Pu-yan C; Pei-hong L
    Vaccine; 2008 Oct; 26(44):5590-4. PubMed ID: 18761388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Five-Year Antibody Persistence Following a Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) Booster in JE-CV-Primed Children in the Philippines.
    Capeding MR; Alberto ER; Bouckenooghe A; Laot TM; Chansinghakul D; Monfredo C; Machabert T; Feroldi E
    J Infect Dis; 2018 Jan; 217(4):567-571. PubMed ID: 29325161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.